Active not recruitingPHASE1INTERVENTIONAL

A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

At a glance

Status

Active not recruiting

Phase

PHASE1

Sponsor

Eisai Inc.

Enrolment target

Start

01 Apr 2020

Estimated completion

31 Mar 2027

Receptors, Estrogen Genes, Erbb-2 Breast Neoplasms

What is this study about?

The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- breast cancer.

Who may be eligible?

Age 18 Years to any · Sex: FEMALE

Locations (8)

Florida Cancer Specialists South - SCRI - PPDS
Sarasota, United States
Massachusetts General Hospital
Boston, United States
Saint Luke's Cancer Institute
Kansas City, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, United States
Tennessee Oncology, PLLC - SCRI - PPDS
Nashville, United States
Royal Marsden NHS Foundation Trust
London, United Kingdom
Sarah Cannon Research Institute UK - SCRI
London, United Kingdom
Royal Marsden NHS Foundation Trust
Sutton, United Kingdom

A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

At a glance

What is this study about?

Who may be eligible?

Locations (8)

How to find out more

Discussion

Community discussion